User profiles for Patrick Durez
 | patrick durezProfesseur académique UCLouvain Verified email at uclouvain.be Cited by 15070 |
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
…, H Burkhardt, M Cardiel, B Combe, P Durez… - Annals of the …, 2016 - ard.bmj.com
Background Reaching the therapeutic target of remission or low-disease activity has
improved outcomes in patients with rheumatoid arthritis (RA) significantly. The treat-to-target …
improved outcomes in patients with rheumatoid arthritis (RA) significantly. The treat-to-target …
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a …
Background Remission and radiographic non-progression are goals in the treatment of early
rheumatoid arthritis. The aim of the combination of methotrexate and etanercept in active …
rheumatoid arthritis. The aim of the combination of methotrexate and etanercept in active …
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis
…, MH Gold, Psoriasis Study Group, P Durez… - Science translational …, 2010 - science.org
Interleukin-17A (IL-17A) is elaborated by the T helper 17 (T H 17) subset of T H cells and
exhibits potent proinflammatory properties in animal models of autoimmunity, including collagen…
exhibits potent proinflammatory properties in animal models of autoimmunity, including collagen…
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve‐month results of a phase IIb, double‐blind, randomized, placebo …
Objective To determine the clinical efficacy, safety, and immunogenicity of abatacept (CTLA‐4Ig),
a selective costimulation modulator, in patients with rheumatoid arthritis (RA) that has …
a selective costimulation modulator, in patients with rheumatoid arthritis (RA) that has …
Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active …
…, EC Hsia, I Strusberg, P Durez… - … : Official Journal of …, 2009 - Wiley Online Library
Objective To assess the safety and efficacy of golimumab in methotrexate (MTX)–naive
patients with active rheumatoid arthritis (RA). Methods MTX‐naive patients with RA (n = 637) …
patients with active rheumatoid arthritis (RA). Methods MTX‐naive patients with RA (n = 637) …
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
…, S Nayiager, J Wollenhaupt, P Durez… - Annals of the …, 2009 - ard.bmj.com
Objectives: To assess the efficacy and safety of abatacept in methotrexate-naive patients
with early rheumatoid arthritis (RA) and poor prognostic factors. Methods: In this double-blind, …
with early rheumatoid arthritis (RA) and poor prognostic factors. Methods: In this double-blind, …
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a …
Background Clinical remission and low disease activity are essential treatment targets in
patients with rheumatoid arthritis. Although moderately active rheumatoid arthritis is common, …
patients with rheumatoid arthritis. Although moderately active rheumatoid arthritis is common, …
Role of interleukin‐4 and interleukin‐10 in murine collagen‐induced arthritis. Protective effect of interleukin‐4 and interleukin‐10 treatment on cartilage destruction
LAB Joosten, E Lubberts, P Durez… - … : Official Journal of …, 1997 - Wiley Online Library
Objective. To examine the role of endogenous interleukin‐4 (IL‐4) and interleukin‐10 (IL‐10)
and the therapeutic effect of the addition of IL‐4 and IL‐10 in early and established murine …
and the therapeutic effect of the addition of IL‐4 and IL‐10 in early and established murine …
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study
MC Genovese, P Durez, HB Richards… - Annals of the …, 2013 - ard.bmj.com
Objective To assess the safety and efficacy of secukinumab, a fully human monoclonal anti-interleukin-17A
antibody, in patients with rheumatoid arthritis (RA). Methods Patients (n=237) …
antibody, in patients with rheumatoid arthritis (RA). Methods Patients (n=237) …
Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double‐blind …
…, E Mysler, L Bessette, C Peterfy, P Durez… - Arthritis & …, 2019 - Wiley Online Library
Objective To evaluate the efficacy, including capacity for inhibition of radiographic
progression, and safety of upadacitinib, a JAK 1‐selective inhibitor, as compared to placebo or …
progression, and safety of upadacitinib, a JAK 1‐selective inhibitor, as compared to placebo or …